person · Reporting owner

Alberttis Alvaro Daniel

Disclosed activity across 1 company

Tapewire entity: 143186
SEC CIK: 0001801089

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
PANACEA LIFE SCIENCES HOLDINGS, INC.EXDI · Entity 9699	Director · CHIEF OPERATING OFFICER	January 22, 2021	February 02, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PANACEA LIFE SCIENCES HOLDINGS, INC.

Report date January 22, 2021 · Filed February 02, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	4,777,337	Reported balance After 2021-01-22 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-01-22 · Grant · Acquired 2,039,241 · Balance 4,777,337 F1: The reporting person was issued a total of 2,039,241 shares of common stock in payment of accrued compensation. F2: Consists of 2,277,337 shares of common stock, together with options to purchase 2,500,00 shares of common stock at a price of $0.025 per share, exercisable until 1/22/23.
Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2023-01-22	Direct	2,500,000	Reported balance After 2021-01-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-01-22 · Grant · Acquired 2,500,000 · Balance 2,500,000 F3: (1) The reporting person was granted two year options to purchase 2,500,000 shares of Common Stock at an exercise price of $0.025 per share. Provided Mr. Alberttis has not resigned or been removed prior to vesting, fifty (50%) percent of such amount shall vest upon his execution of the Corporation's Annual Report on Form 10-K for filing with the SEC for the Corporation's fiscal year ended December 31, 2020 on or prior to the due date thereof, including any and all Certifications thereto required to be executed by Mr. Alberttis under the Sarbanes-Oxley Act of 2002 (as well as any amendments and any other SEC filings or reports as requested) and fifty (50%) percent upon the closing of any acquisition with a combined value (target and the Corporation) in excess of five million ($5,000,000) dollars (the "Acquisition"). (continued, see Footnote 4) F4: (cont'd) Upon closing of an Acquisition, all options shall immediately vest if, and only if, a new chief financial and chief executive officer is appointed who will be responsible for filing and certifying the Form 10-K, provided Mr. Alberttis shall also be required to render reasonable assistance in connection therewith upon request.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person was issued a total of 2,039,241 shares of common stock in payment of accrued compensation.

F2: Consists of 2,277,337 shares of common stock, together with options to purchase 2,500,00 shares of common stock at a price of $0.025 per share, exercisable until 1/22/23.

F3: (1) The reporting person was granted two year options to purchase 2,500,000 shares of Common Stock at an exercise price of $0.025 per share. Provided Mr. Alberttis has not resigned or been removed prior to vesting, fifty (50%) percent of such amount shall vest upon his execution of the Corporation's Annual Report on Form 10-K for filing with the SEC for the Corporation's fiscal year ended December 31, 2020 on or prior to the due date thereof, including any and all Certifications thereto required to be executed by Mr. Alberttis under the Sarbanes-Oxley Act of 2002 (as well as any amendments and any other SEC filings or reports as requested) and fifty (50%) percent upon the closing of any acquisition with a combined value (target and the Corporation) in excess of five million ($5,000,000) dollars (the "Acquisition"). (continued, see Footnote 4)

F4: (cont'd) Upon closing of an Acquisition, all options shall immediately vest if, and only if, a new chief financial and chief executive officer is appointed who will be responsible for filing and certifying the Form 10-K, provided Mr. Alberttis shall also be required to render reasonable assistance in connection therewith upon request.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 22, 2021 Filed Feb 2, 2021 18:57 UTC	PANACEA LIFE SCIENCES HOLDINGS, INC. EXDI · Entity 9699	GrantOptions to purchase common stock · Derivative	2,500,000	$0.03 Strike: $0.03	$62,500.00	Disclosure SEC source: 0001415889-21-000480 · form4-02022021_100218.xml · derivative · entry 2 Alberttis Alvaro Daniel · CIK 0001801089 · Director · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500,000 Underlying: Common stock · 2,500,000 shares Expires 2023-01-22 F3 · derivative.exercise_date: (1) The reporting person was granted two year options to purchase 2,500,000 shares of Common Stock at an exercise price of $0.025 per share. Provided Mr. Alberttis has not resigned or been removed prior to vesting, fifty (50%) percent of such amount shall vest upon his execution of the Corporation's Annual Report on Form 10-K for filing with the SEC for the Corporation's fiscal year ended December 31, 2020 on or prior to the due date thereof, including any and all Certifications thereto required to be executed by Mr. Alberttis under the Sarbanes-Oxley Act of 2002 (as well as any amendments and any other SEC filings or reports as requested) and fifty (50%) percent upon the closing of any acquisition with a combined value (target and the Corporation) in excess of five million ($5,000,000) dollars (the "Acquisition"). (continued, see Footnote 4) F4 · derivative.exercise_date: (cont'd) Upon closing of an Acquisition, all options shall immediately vest if, and only if, a new chief financial and chief executive officer is appointed who will be responsible for filing and certifying the Form 10-K, provided Mr. Alberttis shall also be required to render reasonable assistance in connection therewith upon request. Read SEC document
January 22, 2021 Filed Feb 2, 2021 18:57 UTC	PANACEA LIFE SCIENCES HOLDINGS, INC. EXDI · Entity 9699	GrantCommon stock	2,039,241	$0.03	$50,981.03	Disclosure SEC source: 0001415889-21-000480 · form4-02022021_100218.xml · nonDerivative · entry 1 Alberttis Alvaro Daniel · CIK 0001801089 · Director · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,777,337 F1 · price: The reporting person was issued a total of 2,039,241 shares of common stock in payment of accrued compensation. F2 · balance_after: Consists of 2,277,337 shares of common stock, together with options to purchase 2,500,00 shares of common stock at a price of $0.025 per share, exercisable until 1/22/23. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.